Understanding Down Syndrome Screening Result

Read together the type of your test, the reported result, and the ultrasound context; Find out what topics you can discuss in a meeting with your physician.

Medical content owner: Op. Dr. Cem Akaltun, Obstetrician and Gynecologist · English version: AI-assisted translation of the Turkish original, not separately reviewed by a physician · Editorial policy

This tool does not produce a new risk ratio or diagnosis. It does not replace the laboratory result. cfDNA (NIPT/fetal DNA) and serum screening are different tests; A low risk result does not exclude all diseases.

1. Your scan report

Type of previous screening test

What kind of conclusion is written in the report? Select the laboratory's own evaluation. The 1/x ratio is not recalculated here.

2. Your physician's ultrasound report What is the overall context of the report? NT is nuchal translucency in the first trimester; NF is nuchal fold in the second trimester. These are not the same measurement. Do not select “single marker” if there are multiple or structural findings in the report.

Interactive routing requires JavaScript. Screening is not diagnosis; If the test is positive or inconclusive, contact your doctor with your report. The following sources and explanations can be read without JavaScript.

This information is not medical advice. Consult your physician about your individual circumstances.

Method and limits

This page provides explanation and discussion preparation based on the report context. Age risk, laboratory denominator, or ultrasound markers are not multiplied together; A new probability is not calculated for the person. Positive screening, inconclusive cfDNA, structural findings, and multiple markers are handled separately.

In a truly isolated second trimester finding, negative serum screening with negative cfDNA does not always give the same guidance. In addition, there is no need for additional examination to chromosome scanning; This does not mean that symptom-specific monitoring, such as bowel, kidney, or growth, is unnecessary.

Automatic test selection is not available for ARSA and conditions not covered in this limited guidance. Individual genetic counseling may be required in multiple pregnancies, vanishing twins, family history, or other special cases. This tool does not read reports and does not query all of these exceptions.

References

ACOG. Screening for Fetal Chromosomal Abnormalities, Practice Advisory, January 2026. Supersedes PB 226 guidance along with SMFM #74.
Rink BD, Dugoff L, Kuller JA; SMFM. Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance. pregnancy 2025;1:e70139.
Prabhu M, Kuller JA, Biggio JR; SMFM. Consult Series #57: Isolated soft ultrasound markers in the second trimester. 2021; Reapproved in 2025.
Norton ME, Biggio JR, Kuller JA, Blackwell SC; SMFM. Consult Series #42: The role of ultrasound in women who undergo cfDNA screening. 2017; Reapproved in 2024.
Fox NS et al.; SMFM. Consult Series #45: Mild fetal ventriculomegaly. 2018; Reapproved in 2024.

Data usage: Selections are processed in this browser; this form does not store records or transmit selected health information to a server.

Last clinical review: 1 November 2026 .

Prenatal screening letter for the patient · Detailed guide for healthcare professionals

← Back to tools